INOVIO PHARMACEUTICALS, INC. Equity Securities, FV-NI, Unrealized Loss
INOVIO PHARMACEUTICALS, INC. (INO) reported Equity Securities, FV-NI, Unrealized Loss of $1.80 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2022-11-08
- INOVIO PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2022-09-30 was $1.80M, a 295.60% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2022-06-30 was $4.00M.
- INOVIO PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2022-03-31 was $4.80M, a 466.04% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2021-09-30 was $455.00K.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 3 month as first filed | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month |
|---|---|---|---|---|
| 2022-09-30 | $1.80M 10-Q · filed 2022-11-08 | $5.80M derived: sum of 2 quarters · filed 2022-11-08 | $10.60M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $4.00M 10-Q · filed 2022-08-09 | $8.80M 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $4.80M 10-Q · filed 2022-05-10 | |||
| 2021-09-30 | $455.00K 10-Q · filed 2022-11-08 | $318.46K derived: sum of 2 quarters · filed 2022-11-08 | $1.20M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$136.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $711.47K 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | $848.00K 10-Q · filed 2022-05-10 | $847.96K 10-Q · filed 2021-05-10 | ||
| 2020-06-30 | -$4.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $691.46K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $5.05M 10-Q · filed 2021-05-10 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |